Most molecular tests rely on the detection of specific markers (e.g., HER2 or PD-1 detection by immunohistochemistry in tumor tissue (https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm)), which makes the development of guidelines and experimental protocols more straightforward compared with functional assays. Here, ERBB2 is linked to neoplasm.